Important Information for Investors: Deadline to Seek Lead Plaintiff Role in Revance Therapeutics Class Action
New York, NY, February 20, 2025 – The law firm of Kirby McInerney LLP reminds investors that they have until March 4, 2025, to seek the role of lead plaintiff in a federal securities class action lawsuit filed on behalf of investors who acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) securities between February 29, 2024, and December 6, 2024 (“the Class Period”).
Background
Revance Therapeutics is a biotechnology company focused on developing and commercializing therapeutics for aesthetic and neurological conditions. The Company’s lead product candidate, DaxibotulinumtoxinA for Injectable Use (DAXI), is a long-acting formulation of botulinum toxin type A, which is designed to provide longer-lasting effects compared to current botulinum toxin products.
Allegations against Revance
The class action lawsuit alleges that Revance and certain of its executive officers and directors made false and misleading statements and failed to disclose material information during the Class Period. Specifically, the complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose that:
- DAXI had not demonstrated superiority over existing botulinum toxin products in clinical trials;
- DAXI’s safety profile was not superior to existing products;
- DAXI’s commercial prospects were overstated;
- The Company’s clinical trial data was manipulated;
- The Company was experiencing manufacturing issues with DAXI;
Impact on Individual Investors
If you purchased or acquired Revance securities during the Class Period, you may be entitled to compensation. The lead plaintiff role in this litigation gives you the opportunity to be a representative of the class and to make decisions on how the class will be represented. The lead plaintiff may also be able to receive a share of any recovery.
Impact on the World
This class action lawsuit could have significant implications for the biotechnology industry and the investment community as a whole. If the allegations are proven true, it could lead to increased scrutiny of other biotech companies and their reporting practices. Furthermore, it could also impact investor confidence in the biotech sector and potentially lead to increased volatility in stock prices.
Conclusion
If you acquired Revance securities during the Class Period and believe you may be entitled to compensation, it is important that you take action before the March 4, 2025, deadline to seek the role of lead plaintiff. The experienced securities fraud attorneys at Kirby McInerney LLP are dedicated to helping investors recover the losses they have suffered as a result of corporate misconduct. For more information, please contact the firm at 212-371-6001 or by email at [email protected]
You can also visit the firm’s website at www.kmcllp.com for more information about the Revance class action lawsuit and other ongoing securities litigations.
